Apolipoproteins by Mass Spectrometry (WG-APO MS)
Membership
Name |
Position |
Country |
Term |
Time in Office |
|
L.R. Ruhaak |
Chair |
NL |
1st |
2023 01 - 2025 12 |
|
I. Begcevic |
Member |
|
|
|
|
U. Ceglarek |
Member |
DE |
|
|
|
V. Delatour |
Member |
FR |
|
|
|
J. Dittrich |
Member |
DE |
|
|
|
A. Hoofnagle |
Member |
US |
|
|
|
Z. Kuklenyik |
Member / CDC |
US |
|
|
|
A. Lyle |
Member / CDC |
US |
|
|
|
H.W. Vesper |
Member / CDC |
US |
|
|
|
H. Althaus |
IVD Representative/Siemens |
DE |
|
|
|
U. Prinzing |
IVD Representative/Roche |
DE |
|
|
|
C. Cobbaert |
Consultant / Past Chair |
NL |
|
|
|
E. Angles-Cano |
Consultant |
FR |
|
|
|
G.M. Kostner |
Consultant |
AT |
|
|
|
F. Kronenberg |
Consultant |
AT |
|
|
|
L. Deprez |
Consultant / JRC |
BE |
|
|
|
I. Dikaios |
Consultant / JRC |
BE |
|
|
|
_________________________________________________________________________________________________
May 2021

_________________________________________________________________________________________________
April 2021
The AACC podcast on the SI-traceable RMS for standardization of serum apolipoproteins is available at following link:
https://podcasts.apple.com/us/podcast/towards-si-traceable-reference-measurement-system-for/id499883130?i=1000514846446
The associated Journal article is also available for download: https://academic.oup.com/clinchem/article/67/3/478/6040690
_________________________________________________________________________________________________
Terms of Reference
- To achieve standardization of a panel of clinically relevant serum apolipoproteins (apo) A-I, B, C-I, C-II , C-III, E and apo (a) (including qualitative phenotyping where needed). Standardization is done in such a way that measurement results are traceable to SI as outlined in ISO 17511. Other traceability chains will be used in cases where traceability to SI cannot be achieved.
- To evaluate clinical performance and clinical utility of serum apolipoprotein panel(s) for CVD risk stratification and treatment, in comparison to or together with contemporary blood lipids.
Current projects
- Define the analytes / measurands intended to be measured.
- Development of primary and secondary reference materials, including evaluation of commutability.
- Development of an LC-MS/MS-based reference method for the above mentioned analytes that are unaffected by genetic variants, post-translational modifications and other factors. The reference method will meet relevant ISO standards (i.e., ISO 15195).
- Evaluation of the analytical performance of the LC-MS/MS reference method.
- Assessment of the performance of commercially available apolipoprotein assays compared to the reference method using commutable reference materials as well as single donation samples.
- Any reference materials and reference measurement procedures developed will be submitted to JCTLM for review and listing on the JCTLM database.
Future Projects
- Evaluation of clinical performance and clinical utility of the multiplexed apolipoprotein test according to the Test Evaluation framework developed by the EFLM working group on Test Evaluation (Horvath AR et al., CCA, 2014).
List of Corresponding Members, nominated by National Societies
Name |
Full and Affiliate Member Societies |
Sang-Guk Lee |
Korean Society of Clinical Chemistry (KSCC) |
Huseyin Kayadibi |
Turkish Biochemical Society (TBS) |
List of Corresponding Members, nominated by Corporate Members
Name |
Corporate Members |
Matthias Grimmler |
DiaSys |
Zechen Liu |
MINDRAY |
Xiaopeng Wang |
SNIBE |
Working Group Chair's contact
Dr. Lucia Renee RUHAAK
Assistant Professor
Department of Clinical Chemistry and Laboratory Medicine
Leiden University Medical Center
Albinusdreef 2
2333 ZA, Leiden
The Netherlands
E-mail: l.r.ruhaak@lumc.nl